Fierce Medtech Names Cognito Therapeutics as One of Its “Fierce 15” Med Tech Companies of 2021
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#Alzheimers—Cognito Therapeutics today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
Cognito’s lead product is a non-invasive neuromodulation device using gamma frequency technology which received FDA Breakthrough Device Designation. The company will launch a pivotal Phase 3 study in mild-to-moderate Alzheimer’s Disease, and a Phase 2 study in Parkinson’s Disease in the next few months.
The company also recently announced the launch of a Phase 3 study in Mild Cognitive Impairment (MCI), to evaluate the safety, efficacy, and cost-effectiveness of its neuromodulation therapeutic platform in patients treated within Providence Health Plan’s network of neurology specialists. This first of its kind registrational study is expected to begin this Summer, running in parallel to Cognito’s pivotal Phase 3 Alzheimer’s study.
“We’re honored to be recognized as one of the Fierce 15 for our rapid advancement of our clinical programs to treat some of the biggest unmet medical needs facing patients and our health system today,” said Brent Vaughan, CEO at Cognito Therapeutics. “This year, we will launch our registrational Phase 3 programs in Alzheimer’s Disease and MCI, and are excited to be able to advance our novel technology to help patients in need of safe and effective treatments.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Medtech’s 10th annual Fierce 15 selection. This year’s full list of winners can be viewed online at: https://www.fiercebiotech.com/special-reports/fierce-medtechs-2021-fierce-15.
“While we’re not fully out of the woods yet when it comes to COVID-19, the innovations pursued by this year’s class of 15 companies will help the industry evolve, either in step with the pandemic or in spite of it,” said Conor Hale, senior editor of Fierce Medtech.
An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About Fierce Medtech
Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day’s top stories.
About Cognito Therapeutics
Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation treatment of the cognitive and functional symptoms associated with Alzheimer’s disease in individuals diagnosed with mild to moderate Alzheimer’s and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and optogenetics pioneer Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
Contacts
Rebecca Willumson
Fierce Medtech
202-824-5050
rwillumson@questex.com
Kimberly Ha
Cognito Therapeutics
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
